{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T04:05:19Z","timestamp":1793505919476,"version":"4.5.0"},"reference-count":53,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T00:00:00Z","timestamp":1784505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T00:00:00Z","timestamp":1784505600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/501100001826","name":"ZonMw","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001826","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004243","name":"Prinses Beatrix Spierfonds","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004243","id-type":"DOI","asserted-by":"publisher"}]},{"name":"TKI Life Sciences & Health"},{"DOI":"10.13039\/100004339","name":"Sanofi","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BioDrugs"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1007\/s40259-026-00773-1","type":"journal-article","created":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T19:07:29Z","timestamp":1784574449000},"page":"909-923","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Home Infusion With Recombinant Human \u03b1-Glucosidase in Children With Pompe Disease: The Dutch Experience Over 20 Years Across the Spectrum From Classic Infantile to Late-Onset Phenotypes"],"prefix":"10.1007","volume":"40","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2377-3108","authenticated-orcid":false,"given":"Imke A. M.","family":"Ditters","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1276-0931","authenticated-orcid":false,"given":"Hidde H.","family":"Huidekoper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacqueline F.","family":"Hardon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-8700-0591","authenticated-orcid":false,"given":"Michelle E.","family":"Kruijshaar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3359-1324","authenticated-orcid":false,"given":"Ans T.","family":"van der Ploeg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8091-263X","authenticated-orcid":false,"given":"Johanna M. P.","family":"van den Hout","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,20]]},"reference":[{"issue":"9646","key":"773_CR1","doi-asserted-by":"publisher","first-page":"1342","DOI":"10.1016\/S0140-6736(08)61555-X","volume":"372","author":"AT van der Ploeg","year":"2008","unstructured":"van der Ploeg AT, Reuser AJ. Pompe\u2019s disease. Lancet. 2008;372(9646):1342\u201353.","journal-title":"Lancet"},{"issue":"1","key":"773_CR2","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/S2352-4642(21)00308-4","volume":"6","author":"IAM Ditters","year":"2022","unstructured":"Ditters IAM, Huidekoper HH, Kruijshaar ME, Rizopoulos D, Hahn A, Mongini TE, et al. Effect of alglucosidase alfa dosage on survival and walking ability in patients with classic infantile Pompe disease: a multicentre observational cohort study from the European Pompe Consortium. Lancet Child Adolesc Health. 2022;6(1):28\u201337.","journal-title":"Lancet Child Adolesc Health."},{"issue":"2","key":"773_CR3","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1002\/ajmg.a.35662","volume":"161A","author":"D G\u00fcng\u00f6r","year":"2013","unstructured":"G\u00fcng\u00f6r D, Reuser AJ. How to describe the clinical spectrum in Pompe disease? Am J Med Genet A. 2013;161A(2):399\u2013400.","journal-title":"Am J Med Genet A"},{"issue":"15","key":"773_CR4","doi-asserted-by":"publisher","first-page":"1396","DOI":"10.1056\/NEJMoa0909859","volume":"362","author":"AT van der Ploeg","year":"2010","unstructured":"van der Ploeg AT, Clemens PR, Corzo D, Escolar DM, Florence J, Groeneveld GJ, et al. A randomized study of alglucosidase alfa in late-onset Pompe\u2019s disease. N Engl J Med. 2010;362(15):1396\u2013406.","journal-title":"N Engl J Med"},{"issue":"3","key":"773_CR5","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1016\/j.ymgme.2012.09.015","volume":"107","author":"AT van der Ploeg","year":"2012","unstructured":"van der Ploeg AT, Barohn R, Carlson L, Charrow J, Clemens PR, Hopkin RJ, et al. Open-label extension study following the Late-Onset Treatment Study (LOTS) of alglucosidase alfa. Mol Genet Metab. 2012;107(3):456\u201361.","journal-title":"Mol Genet Metab"},{"issue":"4","key":"773_CR6","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1007\/s00415-016-8219-8","volume":"264","author":"B Schoser","year":"2017","unstructured":"Schoser B, Stewart A, Kanters S, Hamed A, Jansen J, Chan K, et al. Survival and long-term outcomes in late-onset Pompe disease following alglucosidase alfa treatment: a systematic review and meta-analysis. J Neurol. 2017;264(4):621\u201330.","journal-title":"J Neurol"},{"key":"773_CR7","doi-asserted-by":"publisher","DOI":"10.1007\/s10545-018-0166-3","author":"JC van der Meijden","year":"2018","unstructured":"van der Meijden JC, Kruijshaar ME, Harlaar L, Rizopoulos D, van der Beek N, van der Ploeg AT. Long-term follow-up of 17 patients with childhood Pompe disease treated with enzyme replacement therapy. J Inherit Metab Dis. 2018. https:\/\/doi.org\/10.1007\/s10545-018-0166-3.","journal-title":"J Inherit Metab Dis"},{"issue":"19","key":"773_CR8","doi-asserted-by":"publisher","first-page":"e1756","DOI":"10.1212\/WNL.0000000000008441","volume":"93","author":"L Harlaar","year":"2019","unstructured":"Harlaar L, Hogrel J-Y, Perniconi B, Kruijshaar ME, Rizopoulos D, Taouagh N, et al. Large variation in effects during 10 years of enzyme therapy in adults with Pompe disease. Neurology. 2019;93(19):e1756\u201367.","journal-title":"Neurology"},{"issue":"9227","key":"773_CR9","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1016\/S0140-6736(00)02533-2","volume":"356","author":"H Van den Hout","year":"2000","unstructured":"Van den Hout H, Reuser AJ, Vulto AG, Loonen MC, Cromme-Dijkhuis A, Van der Ploeg AT. Recombinant human alpha-glucosidase from rabbit milk in Pompe patients. Lancet. 2000;356(9227):397\u20138.","journal-title":"Lancet"},{"issue":"5","key":"773_CR10","doi-asserted-by":"publisher","first-page":"e448","DOI":"10.1542\/peds.113.5.e448","volume":"113","author":"JMP Van den Hout","year":"2004","unstructured":"Van den Hout JMP, Kamphoven JHJ, Winkel LPF, Arts WFM, De Klerk JBC, Loonen MCB, et al. Long-term intravenous treatment of Pompe disease with recombinant human alpha-glucosidase from milk. Pediatrics. 2004;113(5):e448\u201357.","journal-title":"Pediatrics"},{"issue":"3","key":"773_CR11","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1203\/PDR.0b013e3181b24e94","volume":"66","author":"PS Kishnani","year":"2009","unstructured":"Kishnani PS, Corzo D, Leslie ND, Gruskin D, Van der Ploeg A, Clancy JP, et al. Early treatment with alglucosidase alpha prolongs long-term survival of infants with Pompe disease. Pediatr Res. 2009;66(3):329\u201335.","journal-title":"Pediatr Res"},{"key":"773_CR12","first-page":"65","volume":"20","author":"A Hahn","year":"2015","unstructured":"Hahn A, Praetorius S, Karabul N, Diessel J, Schmidt D, Motz R, et al. Outcome of patients with classical infantile Pompe disease receiving enzyme replacement therapy in Germany. JIMD Rep. 2015;20:65\u201375.","journal-title":"JIMD Rep"},{"issue":"3","key":"773_CR13","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1007\/s10545-015-9912-y","volume":"39","author":"CM van Gelder","year":"2016","unstructured":"van Gelder CM, Poelman E, Plug I, Hoogeveen-Westerveld M, van der Beek N, Reuser AJJ, et al. Effects of a higher dose of alglucosidase alfa on ventilator-free survival and motor outcome in classic infantile Pompe disease: an open-label single-center study. J Inherit Metab Dis. 2016;39(3):383\u201390.","journal-title":"J Inherit Metab Dis"},{"issue":"3","key":"773_CR14","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1016\/S1474-4422(24)00518-0","volume":"24","author":"NAME van der Beek","year":"2025","unstructured":"van der Beek NAME, Theunissen MTM, van den Hout JMP, Pijnappel WWM, Schoser B, Lafor\u00eat P, et al. Clinical insights in enzyme replacement therapy for metabolic storage disorders: lessons from Pompe disease. Lancet Neurol. 2025;24(3):230\u201345.","journal-title":"Lancet Neurol"},{"issue":"2","key":"773_CR15","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1212\/01.wnl.0000251268.41188.04","volume":"68","author":"PS Kishnani","year":"2007","unstructured":"Kishnani PS, Corzo D, Nicolino M, Byrne B, Mandel H, Hwu WL, et al. Recombinant human acid [alpha]-glucosidase: major clinical benefits in infantile-onset Pompe disease. Neurology. 2007;68(2):99\u2013109.","journal-title":"Neurology"},{"key":"773_CR16","unstructured":"National Institutes of Health NCI. Common Terminology Criteria for Adverse Events, version 5.0: National Institutes of Health, National Cancer Institute; 2017 [updated November 27. https:\/\/ctep.cancer.gov\/protocoldevelopment\/electronic_applications\/docs\/CTCAE_v5_Quick_Reference_5x7.pdf. Accessed 26 Oct 2025."},{"issue":"6","key":"773_CR17","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1002\/mus.10381","volume":"27","author":"LPF Winkel","year":"2003","unstructured":"Winkel LPF, Kamphoven JHJ, van den Hout HJMP, Severijnen LA, van Doorn PA, Reuser AJJ, et al. Morphological changes in muscle tissue of patients with infantile Pompe\u2019s disease receiving enzyme replacement therapy. Muscle Nerve. 2003;27(6):743\u201351.","journal-title":"Muscle Nerve"},{"key":"773_CR18","unstructured":"Joep H.J. Kamphoven LvdD, Marian A. Kroos, Ans T. van der Ploeg, Dirk J. Duncker, Arnold J.J. Reuser. Both low and high uptake forms of acid a-glucosidase target to muscle of KO mice with Pompe's disease. In: Center EMUM, editor. Pompe's disease; the mouse model as model in the development of enzyme therapy; 2004. p. 90\u2013104. https:\/\/repub.eur.nl\/pub\/15246\/Kamphoven_Joep%20H%20J_18%20feb%202004.pdf: https:\/\/repub.eur.nl\/. Accessed 26 Oct 2025."},{"issue":"Pt 3","key":"773_CR19","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1042\/BJ20050364","volume":"389","author":"Y Zhu","year":"2005","unstructured":"Zhu Y, Li X, McVie-Wylie A, Jiang C, Thurberg BL, Raben N, et al. Carbohydrate-remodelled acid alpha-glucosidase with higher affinity for the cation-independent mannose 6-phosphate receptor demonstrates improved delivery to muscles of Pompe mice. Biochem J. 2005;389(Pt 3):619\u201328.","journal-title":"Biochem J"},{"issue":"4","key":"773_CR20","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1182\/blood.V82.4.1107.1107","volume":"82","author":"A Zimran","year":"1993","unstructured":"Zimran A, Hollak CE, Abrahamov A, van Oers MH, Kelly M, Beutler E. Home treatment with intravenous enzyme replacement therapy for Gaucher disease: an international collaborative study of 33 patients. Blood. 1993;82(4):1107\u20139.","journal-title":"Blood"},{"issue":"2","key":"773_CR21","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1093\/ndt\/gfi221","volume":"21","author":"GE Linthorst","year":"2006","unstructured":"Linthorst GE, Vedder AC, Ormel EE, Aerts JM, Hollak CE. Home treatment for Fabry disease: practice guidelines based on 3 years experience in The Netherlands. Nephrol Dial Transplant. 2006;21(2):355\u201360.","journal-title":"Nephrol Dial Transplant"},{"issue":"6","key":"773_CR22","doi-asserted-by":"publisher","first-page":"984","DOI":"10.1007\/s10545-007-0686-8","volume":"30","author":"J Cox-Brinkman","year":"2007","unstructured":"Cox-Brinkman J, Timmermans RG, Wijburg FA, Donker WE, van de Ploeg AT, Aerts JM, et al. Home treatment with enzyme replacement therapy for mucopolysaccharidosis type I is feasible and safe. J Inherit Metab Dis. 2007;30(6):984.","journal-title":"J Inherit Metab Dis"},{"issue":"6","key":"773_CR23","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1007\/s10545-008-0980-0","volume":"31","author":"S Bagewadi","year":"2008","unstructured":"Bagewadi S, Roberts J, Mercer J, Jones S, Stephenson J, Wraith JE. Home treatment with Elaprase and Naglazyme is safe in patients with mucopolysaccharidoses types II and VI, respectively. J Inherit Metab Dis. 2008;31(6):733\u20137.","journal-title":"J Inherit Metab Dis"},{"issue":"3","key":"773_CR24","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1016\/j.ymgme.2009.04.007","volume":"97","author":"BK Burton","year":"2009","unstructured":"Burton BK, Wiesman C, Paras A, Kim K, Katz R. Home infusion therapy is safe and enhances compliance in patients with mucopolysaccharidoses. Mol Genet Metab. 2009;97(3):234\u20136.","journal-title":"Mol Genet Metab"},{"issue":"2-3","key":"773_CR25","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/j.ymgme.2010.06.011","volume":"101","author":"BK Burton","year":"2010","unstructured":"Burton BK, Guffon N, Roberts J, van der Ploeg AT, Jones SA, investigators HOS. Home treatment with intravenous enzyme replacement therapy with idursulfase for mucopolysaccharidosis type II - data from the Hunter Outcome Survey. Mol Genet Metab. 2010;101(2\u20133):123\u20139.","journal-title":"Mol Genet Metab"},{"key":"773_CR26","doi-asserted-by":"publisher","DOI":"10.3390\/jcm14030842","author":"B Kie\u0107-Wilk","year":"2025","unstructured":"Kie\u0107-Wilk B, Guijt P, Dan M, Abdelwahab M, Revel-Vilk S, Serratrice C. Home enzyme replacement therapy in Gaucher Disease: a review. J Clin Med. 2025. https:\/\/doi.org\/10.3390\/jcm14030842.","journal-title":"J Clin Med"},{"issue":"5","key":"773_CR27","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1007\/s40259-023-00609-2","volume":"37","author":"IAM Ditters","year":"2023","unstructured":"Ditters IAM, van Kooten HA, van der Beek N, Hardon JF, Ismailova G, Brusse E, et al. Home-based infusion of Alglucosidase Alfa can safely be implemented in adults with late-onset Pompe disease: lessons learned from 18,380 infusions. BioDrugs. 2023;37(5):685\u201398.","journal-title":"BioDrugs"},{"issue":"1","key":"773_CR28","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1186\/s13023-023-02715-4","volume":"18","author":"IAM Ditters","year":"2023","unstructured":"Ditters IAM, van der Beek N, Brusse E, van der Ploeg AT, van den Hout JMP, Huidekoper HH. Home-based enzyme replacement therapy in children and adults with Pompe disease; a prospective study. Orphanet J Rare Dis. 2023;18(1):108.","journal-title":"Orphanet J Rare Dis"},{"issue":"1","key":"773_CR29","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1186\/s13023-023-02919-8","volume":"18","author":"A Toscano","year":"2023","unstructured":"Toscano A, Musumeci O, Sacchini M, Ravaglia S, Siciliano G, Fiumara A, et al. Safety outcomes and patients\u2019 preferences for home-based intravenous enzyme replacement therapy (ERT) in Pompe disease and mucopolysaccharidosis type I (MPS I) disorder: COVID-19 and beyond. Orphanet J Rare Dis. 2023;18(1):338.","journal-title":"Orphanet J Rare Dis"},{"issue":"6","key":"773_CR30","doi-asserted-by":"publisher","first-page":"330","DOI":"10.12968\/bjon.2006.15.6.20681","volume":"15","author":"A Milligan","year":"2006","unstructured":"Milligan A, Hughes D, Goodwin S, Richfield L, Mehta A. Intravenous enzyme replacement therapy: better in home or hospital? Br J Nurs. 2006;15(6):330\u20133.","journal-title":"Br J Nurs"},{"key":"773_CR31","first-page":"85","volume":"12","author":"D Concolino","year":"2017","unstructured":"Concolino D, Amico L, Cappellini MD, Cassinerio E, Conti M, Donati MA, et al. Home infusion program with enzyme replacement therapy for Fabry disease: the experience of a large Italian collaborative group. Mol Genet Metab Rep. 2017;12:85\u201391.","journal-title":"Mol Genet Metab Rep"},{"issue":"2","key":"773_CR32","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1007\/s10545-015-9889-6","volume":"39","author":"D G\u00fcng\u00f6r","year":"2016","unstructured":"G\u00fcng\u00f6r D, Kruijshaar ME, Plug I, Rizopoulos D, Kanters TA, Wens SC, et al. Quality of life and participation in daily life of adults with Pompe disease receiving enzyme replacement therapy: 10 years of international follow-up. J Inherit Metab Dis. 2016;39(2):253\u201360.","journal-title":"J Inherit Metab Dis"},{"issue":"10","key":"773_CR33","first-page":"1002","volume":"24","author":"L Nalysnyk","year":"2018","unstructured":"Nalysnyk L, Sugarman R, Cele C, Uyei J, Ward A. Budget impact analysis of Eliglustat for the treatment of Gaucher disease type 1 in the United States. J Manag Care Spec Pharm. 2018;24(10):1002\u20138.","journal-title":"J Manag Care Spec Pharm"},{"issue":"12","key":"773_CR34","doi-asserted-by":"publisher","first-page":"1104","DOI":"10.1111\/j.1365-2362.2010.02363.x","volume":"40","author":"JF Guest","year":"2010","unstructured":"Guest JF, Jenssen T, Houge G, Aaseboe W, T\u00f8ndel C, Svarstad E. Modelling the resource implications of managing adults with Fabry disease in Norway favours home infusion. Eur J Clin Investig. 2010;40(12):1104\u201312.","journal-title":"Eur J Clin Investig"},{"issue":"2","key":"773_CR35","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1002\/humu.24148","volume":"42","author":"DOS de Faria","year":"2021","unstructured":"de Faria DOS, t Groen S, Hoogeveen-Westerveld M, Nino MY, van der Ploeg AT, Bergsma AJ, et al. Update of the Pompe variant database for the prediction of clinical phenotypes: novel disease-associated variants, common sequence variants, and results from newborn screening. Hum Mutat. 2021;42(2):119\u201334.","journal-title":"Hum Mutat"},{"issue":"2","key":"773_CR36","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1007\/s10545-014-9707-6","volume":"38","author":"CM van Gelder","year":"2015","unstructured":"van Gelder CM, Hoogeveen-Westerveld M, Kroos MA, Plug I, van der Ploeg AT, Reuser AJJ. Enzyme therapy and immune response in relation to CRIM status: the Dutch experience in classic infantile Pompe disease. J Inherit Metab Dis. 2015;38(2):305\u201314.","journal-title":"J Inherit Metab Dis"},{"issue":"236\u201343","key":"773_CR37","volume":"195","author":"E Poelman","year":"2018","unstructured":"Poelman E, Hoogeveen-Westerveld M, Kroos-de Haan MA, van den Hout JMP, Bronsema KJ, van de Merbel NC, et al. High sustained antibody titers in patients with classic infantile Pompe disease following immunomodulation at start of enzyme replacement therapy. J Pediatr. 2018;195(236\u201343):e3.","journal-title":"J Pediatr"},{"key":"773_CR38","unstructured":"Subjects CCoRIH. L4. SAEs: Central Committee on Research Involving Human Subjects. https:\/\/english.ccmo.nl\/investigators\/standard-research-file-for-research-subject-to-the-dutch-wmo-act\/l-safety-information\/l4-saes. Accessed 26 Oct 2025."},{"issue":"1","key":"773_CR39","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1186\/s13023-019-1039-z","volume":"14","author":"E Poelman","year":"2019","unstructured":"Poelman E, Hoogeveen-Westerveld M, van den Hout JMP, Bredius RGM, Lankester AC, Driessen GJA, et al. Effects of immunomodulation in classic infantile Pompe patients with high antibody titers. Orphanet J Rare Dis. 2019;14(1):71.","journal-title":"Orphanet J Rare Dis"},{"key":"773_CR40","doi-asserted-by":"crossref","unstructured":"Poelman E, van den Dorpel J, Hoogeveen-Westerveld M, van den Hout J, van der Giessen LJ, van der Beek N, et al. Effects of higher and more frequent dosing of alglucosidase alfa and immunomodulation on long-term clinical outcome of classic infantile Pompe patients. J Inherit Metab Dis. 2020;43(6):1243\u201353.","DOI":"10.1002\/jimd.12268"},{"key":"773_CR41","doi-asserted-by":"publisher","first-page":"1336599","DOI":"10.3389\/fimmu.2024.1336599","volume":"15","author":"HA Chen","year":"2024","unstructured":"Chen HA, Hsu RH, Fang CY, Desai AK, Lee NC, Hwu WL, et al. Optimizing treatment outcomes: immune tolerance induction in Pompe disease patients undergoing enzyme replacement therapy. Front Immunol. 2024;15:1336599.","journal-title":"Front Immunol"},{"key":"773_CR42","doi-asserted-by":"crossref","unstructured":"Theunissen MTM DI, van Kooten HA, van Doorn PA, van den Hout JMP, Hoogeveen-Westerveld M, Jacobs E, van der Ploeg AT, van der Beek NAME. Antibody formation and efficacy of enzyme replacement therapy in adults with Pompe disease: unlocking long-term insights. Genet Med. 2026 (under review).","DOI":"10.1016\/j.gim.2026.102578"},{"issue":"1","key":"773_CR43","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1186\/s13023-022-02175-2","volume":"17","author":"HA van Kooten","year":"2022","unstructured":"van Kooten HA, Ditters IAM, Hoogeveen-Westerveld M, Jacobs EH, van den Hout JMP, van Doorn PA, et al. Antibodies against recombinant human alpha-glucosidase do not seem to affect clinical outcome in childhood onset Pompe disease. Orphanet J Rare Dis. 2022;17(1):31.","journal-title":"Orphanet J Rare Dis"},{"key":"773_CR44","first-page":"63","volume":"34","author":"Z Karimian","year":"2017","unstructured":"Karimian Z, Whitley CB, Rudser KD, Utz JRJ. Delayed infusion reactions to enzyme replacement therapies. JIMD Rep. 2017;34:63\u201370.","journal-title":"JIMD Rep."},{"issue":"4","key":"773_CR45","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.1016\/j.jaci.2021.02.012","volume":"147","author":"A Cianferoni","year":"2021","unstructured":"Cianferoni A. Non-IgE-mediated anaphylaxis. J Allergy Clin Immunol. 2021;147(4):1123\u201331.","journal-title":"J Allergy Clin Immunol"},{"key":"773_CR46","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21197213","author":"RP Limgala","year":"2020","unstructured":"Limgala RP, Fikry J, Veligatla V, Goker-Alpan O. The interaction of innate and adaptive immunity and stabilization of mast cell activation in management of infusion related reactions in patients with Fabry Disease. Int J Mol Sci. 2020. https:\/\/doi.org\/10.3390\/ijms21197213.","journal-title":"Int J Mol Sci"},{"issue":"1","key":"773_CR47","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1186\/s13023-025-03844-8","volume":"20","author":"F Spataro","year":"2025","unstructured":"Spataro F, Solimando AG, Desantis V, Vacca A, Di Girolamo A, Ria R. How to manage hypersensitivity reactions to enzyme replacement therapy in lysosomal storage diseases? Orphanet J Rare Dis. 2025;20(1):287.","journal-title":"Orphanet J Rare Dis"},{"issue":"7","key":"773_CR48","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1007\/s11882-021-01018-7","volume":"21","author":"SR Joshi","year":"2021","unstructured":"Joshi SR, Khan DA. Non-IgE-mediated drug hypersensitivity reactions. Curr Allergy Asthma Rep. 2021;21(7):41.","journal-title":"Curr Allergy Asthma Rep"},{"issue":"6","key":"773_CR49","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1097\/MOP.0b013e3282f161f2","volume":"19","author":"TA Burrow","year":"2007","unstructured":"Burrow TA, Hopkin RJ, Leslie ND, Tinkle BT, Grabowski GA. Enzyme reconstitution\/replacement therapy for lysosomal storage diseases. Curr Opin Pediatr. 2007;19(6):628\u201335.","journal-title":"Curr Opin Pediatr"},{"issue":"1\u20132","key":"773_CR50","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1016\/j.ymgme.2011.07.004","volume":"104","author":"AH El-Gharbawy","year":"2011","unstructured":"El-Gharbawy AH, Mackey J, DeArmey S, Westby G, Grinnell SG, Malovrh P, et al. An individually, modified approach to desensitize infants and young children with Pompe disease, and significant reactions to alglucosidase alfa infusions. Mol Genet Metab. 2011;104(1\u20132):118\u201322.","journal-title":"Mol Genet Metab"},{"issue":"5","key":"773_CR51","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1007\/s10545-012-9451-8","volume":"35","author":"C Regnery","year":"2012","unstructured":"Regnery C, Kornblum C, Hanisch F, Vielhaber S, Strigl-Pill N, Grunert B, et al. 36 months observational clinical study of 38 adult Pompe disease patients under alglucosidase alfa enzyme replacement therapy. J Inherit Metab Dis. 2012;35(5):837\u201345.","journal-title":"J Inherit Metab Dis"},{"issue":"3","key":"773_CR52","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1159\/000446154","volume":"169","author":"M Capanoglu","year":"2016","unstructured":"Capanoglu M, Dibek Misirlioglu E, Azkur D, Vezir E, Guvenir H, Gunduz M, et al. IgE-mediated hypersensitivity and desensitisation with recombinant enzymes in Pompe disease and type I and type VI mucopolysaccharidosis. Int Arch Allergy Immunol. 2016;169(3):198\u2013202.","journal-title":"Int Arch Allergy Immunol"},{"key":"773_CR53","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1038\/gim.2016.70","volume":"19","author":"JM de Vries","year":"2017","unstructured":"de Vries JM, Kuperus E, Hoogeveen-Westerveld M, Kroos MA, Wens SCA, Stok M, et al. Pompe disease in adulthood: effects of antibody formation on enzyme replacement therapy. Genet Med. 2017;19:90.","journal-title":"Genet Med"}],"container-title":["BioDrugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40259-026-00773-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40259-026-00773-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40259-026-00773-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,13]],"date-time":"2026-09-13T09:02:43Z","timestamp":1789290163000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40259-026-00773-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,20]]},"references-count":53,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["773"],"URL":"https:\/\/doi.org\/10.1007\/s40259-026-00773-1","relation":{},"ISSN":["1173-8804","1179-190X"],"issn-type":[{"value":"1173-8804","type":"print"},{"value":"1179-190X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,20]]},"assertion":[{"value":"3 March 2026","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 July 2026","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study was partly supported by ZonMw, Prinses Beatrix Spierfonds, TKI Life Sciences & Health, and Sanofi.","order":1,"name":"Ethics","label":"Funding","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"I.A.M. Ditters, J.F. Hardon, M.E. Kruijshaar declare no competing interests. H.H. Huidekoper received funding for research and advisory fees from Biomarin under agreements with Erasmus MC University Medical Center and the relevant industry. J.M.P. van den Hout and A.T. van der Ploeg received funding for research, clinical trials and as advisor from various industries working on enzyme-replacement therapy or next-generation therapies in the field of Pompe disease, other lysosomal storage diseases or neuromuscular disorders, under agreements with Erasmus MC University Medical Center and the relevant industry.","order":2,"name":"Ethics","label":"Competing interest statement","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the medical ethical committee of the Erasmus MC (2007-103).","order":3,"name":"Ethics","label":"Ethics declaration","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Written informed consent was obtained from all patients and\/or their parents\/legal guardians.","order":4,"name":"Ethics","label":"Consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Our paper does not contain any identifiable photos or patient data.","order":5,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"De\u00adidentified data will be shared upon request to the corresponding author from any qualified investigator for the sole purpose of replicating procedures and results presented in the Article, in agreement with EU legislation on the General Data Protection Regulation.","order":6,"name":"Ethics","label":"Data availability","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Conceptualization: ID, JvdH, HH, MK, AvdP. Data curation: ID. Formal analysis: ID. Funding acquisition: JvdH, HH, AvdP. Investigation: ID, HH, JvdH. Methodology: ID, JvdH, HH, AvdP. Project administration: ID, JvdH, AvdP. Resources: ID, JvdH, HH, JH Supervision: JvdH, HH, AvdP. Validation: ID, JvdH. Visualization: ID. Writing\u2014original draft: ID. Writing\u2014review and editing: ID, JvdH, HH, MK, AvdP.","order":7,"name":"Ethics","label":"Author contributions","group":{"name":"EthicsHeading","label":"Declarations"}}]}}